NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.

ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.

WTI posts narrower-than-expected Q2 loss as lower costs offset weaker output and declining revenues.

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the...

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the...

KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.

KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.